Department of Radiology and Nuclear Medicine, University Hospital Brno, Jihlavská 20, Brno, 625 00, Czech Republic.
Department of Radiology and Nuclear Medicine, Medical Faculty, Masaryk University, Brno, 625 00, Czechia.
Cancer Imaging. 2024 Aug 19;24(1):110. doi: 10.1186/s40644-024-00761-0.
To evaluate and compare the diagnostic power of [F]FLT-PET with ceMRI in patients with brain tumours or other focal lesions.
121 patients with suspected brain tumour or those after brain tumour surgery were enroled in this retrospective study (61 females, 60 males, mean age 37.3 years, range 1-80 years). All patients underwent [F]FLT-PET/MRI with gadolinium contrast agent application. In 118 of these patients, a final diagnosis was made, verified by histopathology or by follow-up. Agreement between ceMRI and [F]FLT-PET of the whole study group was established. Further, sensitivity and specificity of ceMRI and [F]FLT-PET were calculated for differentiation of high-grade vs. low-grade tumours, high-grade vs. low-grade tumours together with non-tumour lesions and for differentiation of high-grade tumours from all other verified lesions.
[F]FLT-PET and ceMRI findings were concordant in 119 cases (98%). On closer analysis of a subset of 64 patients with verified gliomas, the sensitivity and specificity of both PET and ceMRI were identical (90% and 84%, respectively) for differentiating low-grade from high-grade tumours, if the contrast enhancement and [F]FLT uptake were considered as hallmarks of high-grade tumour. For differentiation of high-grade tumours from low-grade tumours and lesions of nontumorous aetiology (e.g., inflammatory lesions or post-therapeutic changes) in a subgroup of 93 patients by visual evaluation, the sensitivity of both PET and ceMRI was 90%, whereas the specificity of PET was slightly higher (61%) compared to ceMRI (57%). By receiver operating characteristic analysis, the sensitivity and specificity were 82% and 74%, respectively, when the threshold of SUVmax in the tumour was set to 0.9 g/ml.
We demonstrated a generally very high correlation of [F]FLT accumulation with contrast enhancement visible on ceMRI and a comparable diagnostic yield in both modalities for differentiating high-grade tumours from low-grade tumours and lesions of other aetiology.
评估并比较 [F]FLT-PET 与 ceMRI 在脑肿瘤或其他局灶性病变患者中的诊断效能。
本回顾性研究纳入了 121 例疑似脑肿瘤或脑肿瘤手术后的患者(女性 61 例,男性 60 例,平均年龄 37.3 岁,范围 1-80 岁)。所有患者均行 [F]FLT-PET/MRI 检查,并应用钆造影剂。在这 118 例患者中,通过组织病理学或随访确定了最终诊断。建立了整个研究组中 ceMRI 和 [F]FLT-PET 的一致性。进一步计算了 ceMRI 和 [F]FLT-PET 对高级别与低级别肿瘤、高级别与低级别肿瘤和非肿瘤病变以及高级别肿瘤与所有其他经证实病变进行区分的敏感性和特异性。
[F]FLT-PET 和 ceMRI 的检查结果在 119 例(98%)中一致。在对 64 例经证实的脑胶质瘤患者的亚组进行更仔细的分析时,如果将对比增强和 [F]FLT 摄取视为高级别肿瘤的标志,那么两种 PET 和 ceMRI 对低级别和高级别肿瘤的区分的敏感性和特异性均相同(分别为 90%和 84%)。对于在 93 例患者的亚组中通过视觉评估区分高级别肿瘤与低级别肿瘤和非肿瘤病因(如炎症性病变或治疗后改变),两种 PET 和 ceMRI 的敏感性均为 90%,而 PET 的特异性略高于 ceMRI(分别为 61%和 57%)。通过受试者工作特征分析,当肿瘤的 SUVmax 阈值设定为 0.9 g/ml 时,敏感性和特异性分别为 82%和 74%。
我们证明了 [F]FLT 摄取与 ceMRI 上可见的对比增强之间存在高度相关性,并且两种模态在区分高级别肿瘤与低级别肿瘤和其他病因的病变方面具有相当的诊断效能。